• ERK Inhibition Reduces Mitochondrial Fragmentation in OGD/R

  2026-05-13

  Yuan et al. reveal that ERK inhibition protects neuronal cells from oxygen-glucose deprivation/reoxygenation (OGD/R) injury by downregulating autophagy and mitigating mitochondrial fragmentation. This mechanistic insight clarifies the ERK-Drp1/Mfn2-autophagy axis in cerebral ischemia-reperfusion injury and suggests new avenues for neuroprotection.

• 5-Azacytidine: Dormancy Induction and Metastasis Suppression

  2026-05-13

  Explore how 5-Azacytidine (5-AzaC) functions as a DNA demethylation agent, not only reactivating silenced genes but also inducing cancer cell dormancy to suppress metastasis. This article uniquely translates recent mechanistic insights into actionable assay strategies for advanced oncology research.

• BMS 599626: Mechanistic Precision for Translational Oncology

  2026-05-12

  Explore how BMS 599626 dihydrochloride, a highly selective EGFR and ErbB2 inhibitor, delivers mechanistic clarity and strategic advantage for translational researchers. This article bridges robust experimental rationale, competitive intelligence, and recent advances in senescence and AI-driven drug discovery, guiding the next wave of breakthroughs in breast and lung cancer models.

• Oltipraz for MASLD Models: Beyond Nrf2 to Autophagy and Ferr

  2026-05-12

  Explore how Oltipraz, a potent Nrf2 activator, uniquely enables MASLD and liver disease research by bridging detoxification, autophagy, and ferroptosis pathways. Discover nuanced assay protocols and evidence-based insights distinct from standard chemoprevention workflows.

• Mifepristone (RU486): Advancing Oncology and Reproductive Re

  2026-05-11

  This thought-leadership article explores how Mifepristone (RU486) transcends its contraceptive origins, driving innovation in oncology and reproductive biology through mechanistic insight, experimental rigor, and application strategy. Drawing on current literature and advanced protocol recommendations, it offers translational researchers guidance for maximizing reproducibility and impact with APExBIO’s high-purity RU486.

• Targeting SCUBE3: Antibody Inhibition of Oncogenic Signaling

  2026-05-11

  This study reveals SCUBE3 as a critical driver of tumor survival, therapy resistance, and immune evasion, and demonstrates that antibody-mediated SCUBE3 targeting disrupts oncogenic signaling and restores antitumor immunity. The findings establish extracellular SCUBE3 as a promising, previously untapped target for pan-cancer therapeutic strategies.

• BMS 599626 Dihydrochloride: Advanced EGFR/ErbB2 Inhibition I

  2026-05-10

  Explore the molecular precision and translational relevance of BMS 599626 dihydrochloride as an EGFR and ErbB2 inhibitor. This article uniquely examines its mechanistic impact, integration with AI-driven senolytic discovery, and practical assay guidance for cancer research.

• Ganetespib (STA-9090): Unveiling Hsp90 Inhibition in Tumor B

  2026-05-09

  Explore how Ganetespib (STA-9090) advances cancer research through selective Hsp90 chaperone disruption and precise client protein degradation. This article delivers a uniquely mechanistic and translational analysis, highlighting protocol insights and bridging emerging findings to practical assay design.

• Tunicamycin: Applied N-Glycosylation Inhibitor for ER Stress

  2026-05-08

  Tunicamycin enables precise dissection of N-linked glycosylation and ER stress, with robust protocols for both cell and animal models. Leverage APExBIO's high-purity reagent for reproducible inflammation suppression, immune modulation, and glycosylation pathway interrogation.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-08

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, more accurately reflecting the cellular heterogeneity and drug response variability of primary tumors. The model enables detailed investigation of tumor–stroma interactions, drug resistance mechanisms, and personalized therapeutic strategies, advancing preclinical cancer research.

• Dihydrotestosterone (DHT): Protocols and Troubleshooting for

  2026-05-07

  Dihydrotestosterone (DHT) provides robust mechanistic control in androgen receptor signaling and EGFR pathway studies, enabling nuanced interrogation of therapy resistance and neurodegeneration. This guide distills advanced workflows, real-world troubleshooting, and novel insights from recent research, empowering scientists to maximize the translational impact of DHT assays.

• Dehydroepiandrosterone: Mechanisms and Strategy for Translat

  2026-05-07

  This article explores the mechanistic advances and translational strategies involving Dehydroepiandrosterone (DHEA), focusing on its dual roles as a neuroprotection agent and regulator of granulosa cell proliferation. Grounded in biochemical insights and validated workflows, it provides actionable guidance for translational researchers seeking to leverage DHEA in ovarian and neurodegenerative disease models. The discussion contextualizes APExBIO’s DHEA (SKU B1375) within the evolving competitive and experimental landscape, referencing new integrative research on endoplasmic reticulum stress mitigation in ovarian insufficiency. Distinct from conventional product literature, this piece bridges mechanistic rationale and strategic deployment, ensuring relevance for both bench scientists and translational strategists.

• BMS-777607: A Selective c-Met Inhibitor for Platelet and Can

  2026-05-06

  BMS-777607 empowers researchers to precisely inhibit MET signaling for advanced cancer metastasis models and stem cell differentiation workflows. Its high selectivity and robust in vitro and in vivo performance make it a cornerstone for studies targeting apoptosis, metastasis, and megakaryocyte polyploidization.

• Glucocorticoid Receptor Modulation of Hippocampal CYPs Mitig

  2026-05-06

  This study uncovers that pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 enzymes and attenuates phenytoin-induced neurotoxicity via glucocorticoid receptor signaling, independent of PXR. The findings illuminate a previously unrecognized mechanism for neuroprotection in antiepileptic drug therapy, with implications for safer pharmacological interventions.

• SAG: Smoothened Receptor Agonist for Advanced Hedgehog Assay

  2026-05-05

  SAG is a potent Smoothened receptor agonist that enables reliable Hedgehog pathway activation in disease modeling, stem cell maintenance, and neuroprotection research. By leveraging validated workflows and troubleshooting insights, researchers can achieve robust, reproducible outcomes in both basic and translational studies.

15717 records 1/1048 page Next 12345 下5页 Last page